Literature DB >> 9450507

The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake.

J Romero1, R de Miguel, J A Ramos, J J Fernández-Ruiz.   

Abstract

Cannabinoid receptors (CNRs) in basal ganglia are located on striatal efferent neurons which are gamma-aminobutiric acid (GABA)-containing neurons. Recently, we have demonstrated that CN-induced motor inhibition is reversed by GABA-B, but not GABA-A, receptor antagonists, presumably indicating that the activation of CNRs in striatal outflow nuclei, mainly in the substantia nigra, should be followed by an increase of GABA concentrations into the synaptic cleft of GABA-B receptor synapses. The present study was designed to examine whether this was originated by increasing GABA synthesis and/or release or by decreasing GABA uptake. We analyzed: (i) GABA synthesis, by measuring the activity of glutamic acid decarboxylase (GAD) and GABA contents in brain regions that contain striatonigral GABAergic neurons, after in vivo administration of CNs and/or the CNR antagonist SR141716; (ii) [3H]GABA release in vitro in the presence or the absence of a synthetic CN agonist, HU-210, by using perifusion of small fragments of substantia nigra; and (iii) [3H]GABA uptake in vitro in the presence or the absence of WIN-55,212-2, by using synaptosomes obtained from either globus pallidus or substantia nigra. Results were as follows. Delta9-tetrahydrocannabinol (delta9-THC) and HU-210, did not alter neither GAD activity nor GABA contents in both the striatum and the ventral midbrain at any of the two times tested, thus suggesting that CNs apparently failed to change GABA synthesis in striatonigral GABAergic neurons. A similar lack of effect of HU-210 on in vitro [3H]GABA release, both basal and K+-evoked, was seen when this CN was added to perifused substantia nigra fragments, also suggesting no changes at the level of GABA release. However, when synaptosome preparations obtained from the substantia nigra were incubated in the presence of WIN-55,212-2, a decrease in [3H]GABA uptake could be measured. This lowering effect was specific of striatonigral GABAergic neurons since it was not observed in synaptosome preparations obtained from the globus pallidus. In summary, the activation of CNRs located on striatonigral GABAergic neurons, which primarily access to GABA-B receptor synapses, was accompanied by a reduction in neurotransmitter uptake, thus prolonging the presence of GABA into the synaptic cleft. This mechanism might underly the CN-induced motor inhibition through the potentiation of the inhibitory effect of GABA on neuronal activity, in particular of nigrostriatal dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9450507     DOI: 10.1016/s0024-3205(97)01117-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  11 in total

Review 1.  Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output.

Authors:  Megan L Fitzgerald; Eli Shobin; Virginia M Pickel
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-01-11       Impact factor: 5.067

2.  The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.

Authors:  Szabolcs Farkas; Katalin Nagy; Zhisheng Jia; Tibor Harkany; Miklós Palkovits; Sean R Donohou; Victor W Pike; Christer Halldin; Domokos Máthé; László Csiba; Balázs Gulyás
Journal:  Brain Res Bull       Date:  2012-03-07       Impact factor: 4.077

3.  The effects of acute treatment with delta9-THC on exploratory behaviour and memory in the rat.

Authors:  R Hernández-Tristán; C Arévalo; S Canals; M L Leret
Journal:  J Physiol Biochem       Date:  2000-03       Impact factor: 4.158

4.  Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.

Authors:  J Romero; F Berrendero; L García-Gil; J A Ramos; J J Fernández-Ruiz
Journal:  J Mol Neurosci       Date:  1998-10       Impact factor: 3.444

5.  Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons.

Authors:  C C Huang; S W Lo; K S Hsu
Journal:  J Physiol       Date:  2001-05-01       Impact factor: 5.182

6.  Separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ9-THC in humans discriminating Δ9-THC.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2011-10-04       Impact factor: 4.492

7.  Delta(9)-THC-induced cognitive deficits in mice are reversed by the GABA(A) antagonist bicuculline.

Authors:  S A Varvel; E Anum; F Niyuhire; L E Wise; A H Lichtman
Journal:  Psychopharmacology (Berl)       Date:  2004-08-20       Impact factor: 4.530

8.  Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine.

Authors:  Hadi Fathi Moghaddam; Mohammad Javad Khodayar; Seyed Mohammad Zarei Abarghouei; Mehdi Shafiee Ardestani
Journal:  Saudi Pharm J       Date:  2010-05-31       Impact factor: 4.330

9.  The inhibitory effect of anandamide on luteinizing hormone-releasing hormone secretion is reversed by estrogen.

Authors:  Camila Scorticati; Javier Fernández-Solari; Andrea De Laurentiis; Claudia Mohn; Juan P Prestifilippo; Mercedes Lasaga; Adriana Seilicovich; Silvia Billi; Ana Franchi; Samuel M McCann; Valeria Rettori
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-27       Impact factor: 11.205

10.  Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users.

Authors:  Michael J Wesley; Philip M Westgate; William W Stoops; Thomas H Kelly; Lon R Hays; Joshua A Lile
Journal:  Exp Clin Psychopharmacol       Date:  2018-06       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.